
|Videos|July 14, 2016
Dr. Martin Reck on Docetaxel/Ramucirumab in NSCLC
Author(s)Martin Reck, MD
Advertisement
Martin Reck, MD, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, discuses the REVEL trial, a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer (NSCLC).
A significant improvement in overall survival in favor of the combination of docetaxel with ramucirumab, says Reck. An improvement in progression-free survival (PFS) and response rate was also observed.
This important in efficacy was seen independent from histology. An additional analysis was performed on patients who were chemotherapy refractory patients. An additional benefit was seen in this poor prognostic group, said Reck.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5




































